Lipid-Rich Carcinoma of the Breast. A Clinicopathological Study of 49 Cases
Authors:
- 1 May 2008
- journal article
- research article
- Published by SAGE Publications in Tumori Journal
- Vol. 94 (3) , 342-346
Abstract
Aims and Background: Lipid-rich carcinoma is a very rare variant of breast cancer with an aggressive clinical course and poor prognosis. The present study aimed to explore its clinicopathologic characters. Methods and Study Design: We reviewed 3,206 cases treated in two centers in the last 10 years. They all met the criteria of positive oil red O staining, were PAS negative and had the typical histological features included in the study. Their clinical data were collected. The expression of estrogen and progesterone receptors, HER2 and Ki67 was evaluated by immunohistochemistry. Results: Forty-nine patients were diagnosed with lipid-rich carcinomas. They were all female and ranged in age from 22 to 72 years (mean, 45). The presenting symptoms included a breast mass or lump and nipple discharge. Axillary lymph node metastases were found in 79.2% of the patients at the time of surgery. Respectively 100% and 89.8% were negative for estrogen and progesterone receptors, whereas 71.4% were positive for HER2. All patients received surgery plus chemotherapy with or without radiotherapy. In vitro MTT assay showed taxol- or platinum-based chemotherapy to be the most effective. The 2- and 5-year overall survival rates were 64.6% and 33.2%, respectively. Conclusions: Lipid-rich carcinoma has a biopathological profile significantly different from other types of breast cancer, with a predominance of unfavorable prognostic parameters. Early diagnosis and active treatment may be helpful to increase its overall survival.Keywords
This publication has 10 references indexed in Scilit:
- Etiology of Hormone Receptor–Defined Breast Cancer: A Systematic Review of the LiteratureCancer Epidemiology, Biomarkers & Prevention, 2004
- Preferential HER‐2/neu overexpression and/or amplification in aggressive histological subtypes of invasive breast cancerHistopathology, 2004
- Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast CancerJournal of Clinical Oncology, 2002
- Her-2/ neu and Breast CancerDiagnostic Molecular Pathology, 2001
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001
- Metaplastic lipid‐rich carcinoma of the breastPathology International, 1998
- Evaluation of in vitro chemosensitivity of antitumor drugs using the MTT assay in fresh human breast cancerBreast Cancer Research and Treatment, 1998
- Ductal carcinoma of male breast with prominent lipid-rich componentPathology, 1995
- Lipid-rich carcinoma of the breast.A clinicopathologic analysis of 13 examplesCancer, 1974
- Lipid-secreting mammary carcinoma.Report of a case associated with paget's disease of the nippleCancer, 1963